大博医疗: 2025年半年度报告

Core Viewpoint - The report highlights the financial performance and operational status of Double Medical Technology Inc. for the first half of 2025, showcasing significant growth in revenue and net profit, alongside a stable business model in the medical high-value consumables sector. Financial Performance - The company achieved operating revenue of CNY 1,210,439,721.50, representing a year-on-year increase of 25.55% compared to CNY 964,129,205.76 in the same period last year [2][10]. - The net profit attributable to shareholders reached CNY 244,258,762.40, up 76.69% from the previous year, while the net profit after deducting non-recurring gains and losses was CNY 222,695,524.72, reflecting an increase of 82.64% [2][10]. - The basic earnings per share increased by 79.90% to CNY 0.6007 from CNY 0.3339 [2][10]. - The overall gross margin for the reporting period was 71.01% [10]. Business Overview - The main business of the company involves the production, research, and sales of medical high-value consumables, including orthopedic trauma implants, spinal implants, joint implants, sports medicine, and minimally invasive surgical consumables [3][4]. - The company’s product lines showed collaborative growth, with trauma products generating CNY 468,220,039.78 in revenue, a 23.68% increase, and spinal products achieving CNY 217,257,515.06, up 29.86% [10][11]. International Expansion - The company has been actively expanding its international market presence, with products exported to over 70 countries, including Australia, Ukraine, and Chile. The overseas business revenue reached CNY 157,583,735.84, marking a 50.84% increase [11][12]. R&D and Quality Management - The company has established a comprehensive R&D system, holding 110 invention patents and 251 medical device registration certificates, with some products certified by FDA and CE [12][14]. - A strict quality management system is in place to ensure product reliability and safety, which is critical for maintaining the company's reputation in the medical field [14]. Marketing and Sales Strategy - The company employs a distribution-focused sales model, supported by a robust marketing network across more than 30 provinces in China, enhancing its market influence and brand recognition [15][16]. - The marketing strategy includes training programs for distributors and direct engagement with healthcare professionals to promote product awareness and usage [10][11].